Treatment of Idiopathic Multicentric Castleman Disease Without Severe Organ Dysfunction
Patients with idiopathic multicentric Castleman disease (iMCD) who do not meet criteria for severe organ dysfunction represent a distinct clinical sub-group. This protocol addresses their management.
Clinical Scenario
Patients are classified as non-severe iMCD when all of the following apply:
- ECOG performance status below 2
- Estimated glomerular filtration rate (eGFR) at or above 30
- Hemoglobin above 8.0 g/dL
- No anasarca, ascites, or pleural/pericardial effusion
- No interstitial pneumonitis with dyspnea
These patients are typically managed in the outpatient setting and present without evidence of significant organ compromise.
Treatment Approach (Partial Overview)
For patients meeting this profile, therapy with an immunomodulatory or immunosuppressive agent — with or without corticosteroids — is a recognized approach, and expert consultation is recommended. The complete regimen, including agent selection and sequencing, is available in the full protocol.
References
DOI: 10.1182/blood-2018-07-862334
- iMCD patients who are not severely sick are typically diagnosed in the outpatient setting and have a good performance status without evidence of abnormal organ function, whereas other patients are more symptomatic and often exhibit an IL-6–driven inflammatory response that interferes significantly with their ability to function and work.
- Patients should be classified as nonsevere iMCD if the above criteria are not met.
- We recommend use of an immunomodulatory/immunosuppressive agent because these agents have less toxicity than chemotherapy and have similar efficacy (69% response), albeit in fewer case reports.
- These agents include cyclosporine A, sirolimus, thalidomide, lenalidomide, bortezomib, the IL-1b receptor antagonist anakinra, retinoic acid derivatives, and interferon-a.
View source ↗